A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance
- Disease/Condition
- Chronic Hepatitis B
- Drug/Device/Intervention
- PegIFNα2b
- Study type
- Observational
- Intervention type
- drug
- Primary sponsor
- Qilu Hospital of Shandong University
- Location
- Jinan, China
- Phase
- N/A
- Start date
- May 09, 2023
- End date
- Dec 31, 2025
- Enrollment
- 40 participants
HBsAg clearance
The goal of this retrospective observational study is to find out the effects of probiotics
 on HBV clearance. The main question it aims to answer is:
 
 Are the probiotics have an effect in promoting HBV clearance? The participants will observe
 the HBV clearance rate in chronic hepatitis B patients receive probiotics in addition to the
 routine antiviral therapy.
 
 Researchers will compare the HBV clearance rate in chronic hepatitis B patients receive
 probiotics and antiviral therapy with those receiving solely antiviral therapy.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06313255
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06313255 through Pure Global AI's free database. This phase not specified trial is sponsored by Qilu Hospital of Shandong University and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.